SMFG
REGN icon

Sumitomo Mitsui Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Sumitomo Mitsui Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-745
Closed -$1K – 199
2021
Q3 		$1K Buy
+745
New +$463K ﹤0.01% 181

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Financial Group's REGN Position: Q2 2022 in Review

Sumitomo Mitsui Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 96 shares — an estimated $66K sold.

Sumitomo Mitsui Financial Group first reported a position in REGN in Q3 2018 and held it in 5 quarters. The position peaked at $66K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Sumitomo Mitsui Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Sumitomo Mitsui Financial Group sold 96 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $66K.
  • Sumitomo Mitsui Financial Group first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Sumitomo Mitsui Financial Group's Regeneron Pharmaceuticals position peaked at $66K in Q1 2022.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Sumitomo Mitsui Financial Group's 13F filing for Q2 2022, filed 9 Aug 2022.